According to MannKind Corp's latest financial reports the company's current earnings (TTM) are -$10.38 M. In 2022 the company made an earning of -$87.4 M a decrease over its 2021 earnings that were of -$80.93 M.The earnings displayed on this page is the company's Pretax Income.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$10.38 M | -88.13% |
2022 | -$87.4 M | 8% |
2021 | -$80.93 M | 40.84% |
2020 | -$57.46 M | 10.7% |
2019 | -$51.91 M | -40.16% |
2018 | -$86.74 M | -26.04% |
2017 | -$0.12 B | -193.33% |
2016 | $0.12 B | -134.11% |
2015 | -$0.37 B | 85.72% |
2014 | -$0.2 B | 3.6% |
2013 | -$0.2 B | 12.79% |
2012 | -$0.17 B | 5.58% |
2011 | -$0.17 B | -5.72% |
2010 | -$0.18 B | -22.51% |
2009 | -$0.23 B | -27.37% |
2008 | -$0.31 B | 3.36% |
2007 | -$0.3 B | 27.18% |
2006 | -$0.24 B | 101.63% |
2005 | -$0.12 B | 50.46% |
2004 | -$76 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Pfizer PFE | $3.26 B | -31,583.09% | ๐บ๐ธ USA |
Novo Nordisk NVO | $15.42 B | -148,788.45% | ๐ฉ๐ฐ Denmark |
Eli Lilly LLY | $6.55 B | -63,264.69% | ๐บ๐ธ USA |
Merck MRK | $3.03 B | -29,347.37% | ๐บ๐ธ USA |
Halozyme Therapeutics HALO | $0.34 B | -3,456.74% | ๐บ๐ธ USA |
Nektar Therapeutics
NKTR | -$0.28 B | 2,562.20% | ๐บ๐ธ USA |